BIO-PATH HOLDINGS, INC.
BELLAIRE, TX · CIK 0001133818 · Biotech · Public
RNA-based therapeutic molecules targeting cancer and hematologic diseases
biopath.health →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $18M
- 17 Form D · Oct 2024
- 23 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 21
- 9 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $650,000 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Private capital raised | Form D · SEC | $150,000 | |
| Private capital raised | Form D · SEC | $75,000 | |
| Private capital raised | Form D · SEC | $453,000 | |
| Private capital raised | Form D · SEC | $10,000 | |
| Private capital raised | Form D · SEC | $2,301,340 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $83,775 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $987,746 | |
| Private capital raised | Form D · SEC | $1,387,514 | |
| Private capital raised | Form D · SEC | $2,280,000 | |
| Private capital raised | Form D · SEC | $317,929 | |
| Private capital raised | Form D · SEC | $1,275,880 | |
| Private capital raised | Form D · SEC | $3,998,370 | |
| Private capital raised | Form D · SEC | $3,995,403 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2371 | Helicore, LLC | — | $2.0M |
| 2372 | IMMUNE-ONC THERAPEUTICS, INC. | — | $7.0M |
| 2373 | Eluciderm Inc. | — | $3.8M |
| 2374 | BIO-PATH HOLDINGS, INC. | — | $18M |
| 2375 | Indapta Therapeutic | — | — |
| 2376 | BIOINVENU CORPORATION | — | — |
| 2377 | DNP THERAPEUTICS INC | — | $470K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Paul AubertDirector
- Heath CleaverDirector
- Mark ColonneseDirector
- Thomas GarrisonDirector
- MICHAEL GARRISONDirector
- THOMAS GARRISONDirector
- Gillian Ivers-ReadDirector
- GILLIAN IVERS-READDirector
- Douglas MorrisDirector · Executive Officer · Promoter
- DOUGLAS MORRISDirector · Executive Officer · Promoter
- Peter NielsenDirector · Executive Officer · Promoter
- PETER NIELSENDirector · Executive Officer · Promoter
- Aline SherwoodDirector
Patents
- P-ethoxy Nucleic Acids For Liposomal Formulationapplication
- P-ethoxy Nucleic Acids For STAT3 Inhibitiongranted
- P-ethoxy Nucleic Acids For BCL2 Inhibitiongranted
- P-ethoxy Nucleic Acids For Liposomal Formulationgranted
- Combination Therapy With Liposomal Antisense Oligonucleotidesgranted
- P-ethoxy Nucleic Acids For STAT3 Inhibitiongranted
- P-ethoxy Nucleic Acids For IGF-1R Inhibitionapplication
- Combination Therapy With Liposomal Antisense Oligonucleotidesgranted
- P-ethoxy Nucleic Acids For Liposomal Formulationgranted
- P-ethoxy Nucleic Acids For Liposomal Formulationgranted
- P-ethoxy Nucleic Acids For Liposomal Formulationgranted
- P-ethoxy Nucleic Acids For Liposomal Formulationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.